Skip to main content
Top
Published in: Infection 5/2012

01-10-2012 | Clinical and Epidemiological Study

A prospective cohort study on hospital mortality due to Clostridium difficile infection

Authors: J. M. Wenisch, D. Schmid, G. Tucek, H.-W. Kuo, F. Allerberger, V. Michl, P. Tesik, H. Laferl, C. Wenisch

Published in: Infection | Issue 5/2012

Login to get access

Abstract

Purpose

Although an increase in burden of disease has frequently been reported for Clostridium difficile infection (CDI), specific data on the effect of CDI on a patient’s risk of death or overall hospital mortality are scarce. Therefore, we performed a prospective cohort study to analyse the effect of CDI on the risk of pre-discharge all-cause death in all inpatients with CDI compared to all inpatients without CDI during 2009 in a single hospital.

Methods

Clostridium difficile infection was defined as by the European Society of Clinical Microbiology and Infectious Diseases. Data were collected from the medical charts of CDI patients and from the hospital discharge data of non-CDI and CDI patients. The effect measures of CDI used to compute the risk of pre-discharge all-cause death were risk ratio, attributable risk, mortality fraction (%) and population attributable risk percentage. Co-morbidity was categorized using the Charlson co-morbidity score in which a value of ≤2 was defined as low co-morbidity and that of >2 as moderate/severe co-morbidity. A stratified analysis and a Poisson regression model were applied to adjust for the effects of the risk factors sex, age and severity of co-morbidity.

Results

A total of 185 hospitalized patients with CDI were compared to 38,644 other hospitalized patients without CDI admitted between 1 January 2009 and 31 December 2009. The mean age of the CDI and non-CDI patients was 74.3 (range 72.3–76.4) and 51.9 (range 51.6–52.1) years, respectively. Of the 185 CDI, 136 (73.5 %) and 49 (26.5 %) were categorized with low and high co-morbidity, respectively, versus 32,107 (83.4 %) and 6,352 (16.5 %), respectively, in non-CDI patients. Overall, 24 of the 185 CDI patients (13 %) versus 1,021 of the 38,459 non-CDI patients (2.7 %) died during their hospital stay, resulting in a relative risk of pre-discharge death of 4.89 [95 % confidence interval (CI) 3.35–7.13] for CDI patients, a CDI attributable risk of death of 10.3 per 100 patients and a CDI attributable fraction of 79.5 % (95 % CI 70.1–86 %). After adjustment for age, sex and co-morbidity the relative risk of pre-discharge death was 2.74 (95 % CI 1.82–4.10; p < 0.0001) for patients with CDI, and the proportion of hospital deaths due to CDI was 1.72 (95 % CI 1.22–2.05).

Conclusion

The results of this study lead to the conclusion that hospitalized patients with CDI are—independent of age, sex and co-morbidity severity—2.74-fold more likely to die during their hospital stay than all other hospitalized patients. The eradication of CDI in the hospital could have prevented 1.72 % of in-hospital deaths in our study population during the 1 year of the study.
Literature
1.
go back to reference Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis: a prospective study. Ann Intern Med. 1974;81:429–33.PubMed Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis: a prospective study. Ann Intern Med. 1974;81:429–33.PubMed
2.
go back to reference Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591–7.PubMedCrossRef Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591–7.PubMedCrossRef
3.
go back to reference Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60.PubMedCrossRef Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254–60.PubMedCrossRef
4.
go back to reference Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J. 2004;171:466–72.CrossRef Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J. 2004;171:466–72.CrossRef
5.
go back to reference Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J. 2005;173:1037–42.CrossRef Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. Can Med Assoc J. 2005;173:1037–42.CrossRef
6.
go back to reference McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–41.PubMedCrossRef McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–41.PubMedCrossRef
7.
go back to reference Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–84.PubMedCrossRef Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–84.PubMedCrossRef
8.
go back to reference Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2–18.PubMedCrossRef Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2–18.PubMedCrossRef
9.
go back to reference Clements AC, Magalhaes RJ, Tatem AJ, et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis. 2010;10:395–404.PubMedCrossRef Clements AC, Magalhaes RJ, Tatem AJ, et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis. 2010;10:395–404.PubMedCrossRef
10.
go back to reference Joseph R, Demeyer D, Vanrenterghem D, et al. First isolation of Clostridium difficile PCR ribotype 027, toxinotype III in Belgium. Euro Surveill. 2005;10:E051020.4.PubMed Joseph R, Demeyer D, Vanrenterghem D, et al. First isolation of Clostridium difficile PCR ribotype 027, toxinotype III in Belgium. Euro Surveill. 2005;10:E051020.4.PubMed
11.
go back to reference Cheknis AK, Sambol SP, Davidson DM, et al. Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005–2007. Anaerobe. 2009;15:230–3.PubMedCrossRef Cheknis AK, Sambol SP, Davidson DM, et al. Distribution of Clostridium difficile strains from a North American, European and Australian trial of treatment for C. difficile infections: 2005–2007. Anaerobe. 2009;15:230–3.PubMedCrossRef
12.
go back to reference McFarland LV, Clarridge JE, Beneda HW, et al. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a veteran’s administration health care system. Clin Infect Dis. 2007;45:1141–51.PubMedCrossRef McFarland LV, Clarridge JE, Beneda HW, et al. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a veteran’s administration health care system. Clin Infect Dis. 2007;45:1141–51.PubMedCrossRef
13.
go back to reference Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis. 2007;44:238–44.PubMedCrossRef Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis. 2007;44:238–44.PubMedCrossRef
14.
go back to reference Vaishnavi C. Clinical spectrum and pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010;131:487–99.PubMed Vaishnavi C. Clinical spectrum and pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010;131:487–99.PubMed
16.
17.
go back to reference Dubberke ER, Reske KA, Olsen MA, et al. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46:497–504.PubMedCrossRef Dubberke ER, Reske KA, Olsen MA, et al. Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. Clin Infect Dis. 2008;46:497–504.PubMedCrossRef
18.
go back to reference Paladino JA, Schentag JJ. The economics of Clostridium difficile-associated disease for providers and payers. Clin Infect Dis. 2008;46:505–6.PubMedCrossRef Paladino JA, Schentag JJ. The economics of Clostridium difficile-associated disease for providers and payers. Clin Infect Dis. 2008;46:505–6.PubMedCrossRef
19.
go back to reference Zilberberg MD. Clostridium difficile-related hospitalizations among US adults, 2006. Emerg Infect Dis. 2009;15:122–4.PubMedCrossRef Zilberberg MD. Clostridium difficile-related hospitalizations among US adults, 2006. Emerg Infect Dis. 2009;15:122–4.PubMedCrossRef
20.
go back to reference Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15:1067–79.PubMedCrossRef Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect. 2009;15:1067–79.PubMedCrossRef
21.
go back to reference Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef
22.
go back to reference van den Berg RJ, Claas EC, Oyib DH, et al. Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol. 2004;42:1035–41.PubMedCrossRef van den Berg RJ, Claas EC, Oyib DH, et al. Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol. 2004;42:1035–41.PubMedCrossRef
23.
go back to reference Indra A, Schmid D, Huhulescu S, et al. Characterization of clinical Clostridium difficile isolates by PCR ribotyping and detection of toxin genes in Austria, 2006–2007. J Med Microbiol. 2008;57:702–8.PubMedCrossRef Indra A, Schmid D, Huhulescu S, et al. Characterization of clinical Clostridium difficile isolates by PCR ribotyping and detection of toxin genes in Austria, 2006–2007. J Med Microbiol. 2008;57:702–8.PubMedCrossRef
24.
go back to reference Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, US, 2000–2005. Emerg Infect Dis. 2008;14:929–31.PubMedCrossRef Zilberberg MD, Shorr AF, Kollef MH. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, US, 2000–2005. Emerg Infect Dis. 2008;14:929–31.PubMedCrossRef
25.
go back to reference Lyytikainen O, Turunen H, Sund R, et al. Hospitalizations and deaths associated with Clostridium difficile infection, Finland, 1996–2004. Emerg Infect Dis. 2009;15:761–5.PubMedCrossRef Lyytikainen O, Turunen H, Sund R, et al. Hospitalizations and deaths associated with Clostridium difficile infection, Finland, 1996–2004. Emerg Infect Dis. 2009;15:761–5.PubMedCrossRef
26.
go back to reference Indra A, Huhulescu S, Fiedler A, et al. Outbreak of Clostridium difficile 027 infection in Vienna, Austria 2008–2009. Euro Surveill. 2009;14(17):1–2. Indra A, Huhulescu S, Fiedler A, et al. Outbreak of Clostridium difficile 027 infection in Vienna, Austria 2008–2009. Euro Surveill. 2009;14(17):1–2.
27.
go back to reference Kenneally C, Rosini JM, Skrupky LP, et al. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest. 2007;132:418–24.PubMedCrossRef Kenneally C, Rosini JM, Skrupky LP, et al. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest. 2007;132:418–24.PubMedCrossRef
28.
go back to reference Marra AR, Edmond MB, Wenzel RP, et al. Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infect Dis. 2007;7:42.PubMedCrossRef Marra AR, Edmond MB, Wenzel RP, et al. Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome. BMC Infect Dis. 2007;7:42.PubMedCrossRef
29.
go back to reference Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–9.PubMedCrossRef Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–9.PubMedCrossRef
30.
go back to reference Zilberberg MD, Shorr AF, Micek ST, et al. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med. 2009;37:2583–9.PubMedCrossRef Zilberberg MD, Shorr AF, Micek ST, et al. Clostridium difficile-associated disease and mortality among the elderly critically ill. Crit Care Med. 2009;37:2583–9.PubMedCrossRef
31.
go back to reference Curns AT, Steiner CA, Sejvar JJ, et al. Hospital charges attributable to a primary diagnosis of infectious diseases in older adults in the US, 1998–2004. J Am Geriatr Soc. 2008;56:969–75.PubMedCrossRef Curns AT, Steiner CA, Sejvar JJ, et al. Hospital charges attributable to a primary diagnosis of infectious diseases in older adults in the US, 1998–2004. J Am Geriatr Soc. 2008;56:969–75.PubMedCrossRef
32.
go back to reference Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc. 2002;50:S226–9.PubMedCrossRef Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc. 2002;50:S226–9.PubMedCrossRef
33.
go back to reference Zilberberg MD, Shorr AF, Kollef MH. Growth and geographic variation in hospitalizations with resistant infections, US, 2000–2005. Emerg Infect Dis. 2008;14:1756–8.PubMedCrossRef Zilberberg MD, Shorr AF, Kollef MH. Growth and geographic variation in hospitalizations with resistant infections, US, 2000–2005. Emerg Infect Dis. 2008;14:1756–8.PubMedCrossRef
34.
go back to reference Lozniewski A, Rabaud C, Dotto E, et al. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of premier Cytoclone A + B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol. 2001;39:1996–8.PubMedCrossRef Lozniewski A, Rabaud C, Dotto E, et al. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of premier Cytoclone A + B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains. J Clin Microbiol. 2001;39:1996–8.PubMedCrossRef
Metadata
Title
A prospective cohort study on hospital mortality due to Clostridium difficile infection
Authors
J. M. Wenisch
D. Schmid
G. Tucek
H.-W. Kuo
F. Allerberger
V. Michl
P. Tesik
H. Laferl
C. Wenisch
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Infection / Issue 5/2012
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-012-0258-1

Other articles of this Issue 5/2012

Infection 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.